Bioxcel therapeutics announces publication in frontiers in pharmacology on the effects of dexmedetomidine (the active ingredient in bxcl-501) on stress-mediated behaviors in non-clinical studies

Dexmedetomidine demonstrated a significant reduction in stress-induced behaviors, suggesting potential applications of bxcl501 in chronic psychiatric disorders in addition to treatment of acute agitation
BTAI Ratings Summary
BTAI Quant Ranking